CRESCENT BIOPHARMA, INC. - 8-K Filing

Crescent Biopharma reports Q3 2026 net loss of $37.7 million and announces completion of dose escalation in Phase 1/2 ASCEND trial. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 21:15 UTC

Tickers: $CBIO

Read the full article at SEC EDGAR

Part of the story Immix Biopharma, Inc. - 10-Q Filing (3 articles)

More Regulatory news

FACT II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Marblegate Capital Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Greenland Mines Ltd - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
InspireMD, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
InspireMD, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
Pinnacle Acquisition Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:45 UTC
SUTRO BIOPHARMA, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
Aeluma, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
ASTEC INDUSTRIES INC - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
Live Oak Bancshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:44 UTC